Revvity, Inc. (NYSE:RVTY) stock rose Tuesday after the life sciences and diagnostics company released preliminary expectations for the fourth quarter and fiscal year 2025.
The positive movement comes despite broader market pressure, with major indices like the Nasdaq and S&P 500 both slightly down. The broader market is experiencing a mixed day, with the Nasdaq down 0.19% and the S&P 500 falling 0.20%.
The company announced that it will release its fourth-quarter and full-year 2025 financial results on February 2, 2026.
RVTY Q4 Prelim Earnings: 6% Revenue Growth
Preliminary expectations indicate reported revenue growth of approximately 6% for the fourth quarter to approximately $772 million, compared to the consensus of $760.6 million, with full-year revenue projected to reach around $2.855 billion, reflecting a growth rate of about 4% year-over-year compared to the consensus of $2.84 billion.
Revvity expects its 2025 adjusted earnings per share to exceed the upper end of its previous guidance of $4.90 to $5.00.
2026 Considerations
Revvity expects organic growth of 2%-3%, and high single-digit growth in adjusted earnings per share in 2026.
The company expects that existing end market trends will continue into 2026, and it is on track to achieve adjusted operating margins of around 28%.
RVTY Outperforms with Strong Momentum
Revvity is currently trading 11.2% above its 20-day simple moving average (SMA) and 17.5% above its 100-day SMA, demonstrating strong short-term momentum. Shares have decreased by 10.14% over the past 12 months and are positioned closer to their 52-week highs than lows, suggesting a potential rebound.
The RSI is at 59.86, which is considered neutral territory, indicating that the stock is neither overbought nor oversold. Meanwhile, the MACD is above its signal line, suggesting bullish momentum is present.
The combination of neutral RSI and bullish MACD suggests mixed momentum, indicating that traders should watch for potential breakout opportunities.
- Key Resistance: $117.00
- Key Support: $89.50
Analyst Consensus & Recent Actions:
The stock carries a Buy Rating with an average price target of $120.24. Recent analyst moves include:
- Barclays: Overweight (Raised Target to $115.00)
- Wells Fargo: Equal-Weight (Raised Target to $107.00)
- Goldman Sachs: Initiated with Neutral (Target $105.00)
Valuation Insight: While the stock trades at a premium P/E multiple, the strong consensus and 8% expected earnings growth suggest analysts view this growth as justification for the 9% upside to analyst targets.
Benzinga Edge Ranks RVTY’s Market Position
Below is the Benzinga Edge scorecard for Revvity, highlighting its strengths and weaknesses compared to the broader market:
- Momentum: Weak (Score: 18.91/100) — Stock is underperforming the broader market.
- Quality: Neutral (Score: 39.51/100) — Balance sheet remains stable.
- Value: Weak (Score: 16.37/100) — Trading at a steep premium relative to peers.
ETFs with Significant RVTY Holdings
- First Trust Indxx Medical Devices ETF (NASDAQ:MDEV): 2.18% Weight
RVTY’s Positive Price Movement on Earnings Anticipation
RVTY Price Action: Revvity stock closed 6.02% higher at $110.14 on Tuesday, according to Benzinga Pro data.
Photo by T. Schneider via Shutterstock
